Last reviewed · How we verify
Retin-A Micro 0.04% facial acne treatment — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Retin-A Micro 0.04% facial acne treatment (Retin-A Micro 0.04% facial acne treatment) — Bausch Health Americas, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Retin-A Micro 0.04% facial acne treatment TARGET | Retin-A Micro 0.04% facial acne treatment | Bausch Health Americas, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Retin-A Micro 0.04% facial acne treatment CI watch — RSS
- Retin-A Micro 0.04% facial acne treatment CI watch — Atom
- Retin-A Micro 0.04% facial acne treatment CI watch — JSON
- Retin-A Micro 0.04% facial acne treatment alone — RSS
Cite this brief
Drug Landscape (2026). Retin-A Micro 0.04% facial acne treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/retin-a-micro-0-04-facial-acne-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab